IN-DXM-EMRR

Treatment tested

• Nasal Methylprednisolone (MT)

Compared with

• IV Methylprednisolone administration

Other measures (1)

Inclusion Criteria: * Age between 18 and 65 years. * Diagnosis of RRMS with an evolution from diagnosis of 3 months to 10 years. * Kurtzke Expanded Disability Status Scale (EDSS) from 1 to 6 (grade 6 includes patients with unilateral aid to ambulate) * No contraindication for the administration of MP. * Agree to participate in the study by means of a signed informed consent Exclusion Criteria: * Intake of anti-inflammatory steroids in the last 3 days. * Patients with active bacterial, viral or fungal infections or undergoing treatment. * Patients with hypertension. * Patients with diabetes mellitus. * Patients with hypo or hyperthyroidism. * Patients with glaucoma. * Patients with neoplasms. * Diagnosis of systemic diseases such as: cardiovascular, pulmonary, hepatic, endocrine, gastrointestinal, etc. * Patients with suspected or confirmed pregnancy by means of serum or urinary laboratory tests. * Breastfeeding patients. * Patients with a history of resistance to glucocorticoids. * Patients with a history of severe adverse reactions to glucocorticoids. * Patients with a history of hyposmia or anosmia. * Patients diagnosed with active sinusitis. * Patients with allergic rhinitis. * Patients with upper respiratory tract infections. * deviated septum * History of nasal surgery.

This Clinical Trial evaluates the nasal administration of Methylprednisolone as a treatment strategy for Acute Relapses in Multiple Sclerosis